NLS Aprea

Karolinska Development announces that its portfolio company Aprea Therapeutics has enrolled the first patients in the Phase II part of the ongoing PiSARRO clinical study of APR-246 for the treatment of high-grade serous ovarian cancer. “The initiation of the Phase II clinical study marks an important milestone for Aprea,” said Christian S. Schade, President and Chief […]

Karolinska Development has published its Interim Report for the period January to March 2016. Significant events during Karolinska Development’s first quarter this year include Aprea raising SEK 437 million in a Series B financing round from a syndicate of specialist international life science investors. This was the largest ever completed by a Karolinska Development portfolio company and […]

Karolinska Development’s portfolio company Aprea has raised SEK 437 million ($51 million) in a Series B financing round – the largest private financing to date by one of its portfolio companies, and more broadly by any private life science company in Sweden in the last decade. The syndicate was co-led by specialist life sciences investors […]

Aprea AB has announced that dosing has begun in the Phase I/II proof-of-concept clinical trial of APR-246 in combination with chemotherapy in patients with relapsed platinum sensitive high grade serous ovarian cancer. Cancers develop and spread due to the malfunction of the cells’ normal growth control mechanisms. One of the best-known cancer genes is p53 […]

Karolinska Development’s portfolio company Aprea is to evaluate its drug candidate for the treatment of ovarian cancer in a new British study. It is a phase 1b/II study on the pharmaceutical project APR-246, reports Life Science Sweden. The drug candidate is part of a new type of potential cancer drugs that lead the cancer cells […]